Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I just saw. Horrible.
Susan Morgan (RIP) would have been very proud today ... she was a huge fan of Aaron Berg and told me that she sees him going places.
Y/y reduction in Vascepa sales is finally in the single digits:
TRx -7.9%
NRx -6.6%
Ref -9.0%
According to my biological NNs, AI existential risk to humanity is non-trivial
— Elon Musk (@elonmusk) April 1, 2023
I haven't been reading lately.
Curious about what its opinion on Vascepa.
ChatGPT found to give better medical advice than real doctors in blind study: ‘This will be a game changer’ https://t.co/cVYjhUBt2i
— Fox News (@FoxNews) May 2, 2023
Spotify is free. I use it just to listen to Rogan.
A 3-hour discussion between a cardiologist and Joe Rogan - I haven't watched yet but the preview looks very interesting.
Preview:
Remember when Elon Musk bought Twitter, fired 80% of its' employees and Twitter is functioning much better today, despite that reduction?
Weren't you the guy pushing COVID vaccine?
Having one for you.
https://stocktwits.com/rafunrafun/message/522676296
@Dj_Suv
https://stocktwits.com/SanDiegoLiving/message/521910068
He is very credible. Has 10k followers on Twitter.
Got it, thanks. I was thrown off by "medical" embargo, I thought it was something else.
Do you have the specific post where this was mentioned?
Thanks. Can someone point me to that post, please? And what is a medical embargo?
I truly despise this piece of crap.
You have been perpetrating this vile lie against Vascepa for a while and I hope that @Amarincorp sues the snot out of you. @GeoWizz_ can you please educate this lunatic with one of your lovely charts?
— Raf (@ra_fun) April 11, 2023
Also, see 👇👇👇https://t.co/4kEkrIxqh4
The data on Vascepa (EPA) was re analyzed by Dr Nissen and they found no benefit. They had used a pro inflammatory mineral oil in the placebo arm.
— Dr Alo, DO, FACC (@MohammedAlo) February 23, 2023
I guess this will never be answered.
@DLBHATTMD Do you know what's going on with the MITIGATE trial?
— Raf (@ra_fun) April 10, 2023
Preliminary results were scheduled to be presented over a year ago as late-breaker at ESC but that got pulled and nothing has been said since then.
After reading KM's Complaint, is anyone surprised that we didn't get anywhere under this drama queen's leadership?
Paging Nissen.
Paging Steven Nissen 🤡 @ClevelandClinic @CleClinicMD @DLBHATTMD @VietHeartPA @BudoffMd @mmillermd1 @SABOURETCardio @andrewbostom @ErinMichos https://t.co/lBVQj8B9h8
— Raf (@ra_fun) April 5, 2023
With the new BOD and KM's departure, Denner owes us a conference call to address the current state of affairs ... unless he is too busy orchestrating an immediate buyout.
Where do I report fraud? This person is impersonating Amarin's CEO.
https://www.linkedin.com/in/karimmikhail
None sadder than August 2021 when we left our soldiers behind and 13 of these heroes got murdered. Pretty sure that's much much much worse than J6.
No different than their 1g pill.
Hikma launched a .5g version.
https://drugstorenews.com/hikma-launches-generic-vascepa-0
Not a penny for this scumbag KM! He cost us so much money and now he wants to take more from us.
Things just got very interesting!!
Wow
Uptake of Non-Statin Lipid-Lowering Therapies for Secondary Prevention in Community Practice - not good - “As of 2021, only 6.0% of ASCVD patients were on ezetimibe, 1.6% were on a PCSK9i, and 1.3% on icosapent ethyl, with utilization only marginally https://t.co/VL5GvTTfwu… pic.twitter.com/QO8t2B9XlQ
— Dr. James Underberg (@lipiddoc) March 23, 2023
Scripts for week ending March 17, 2023
Drug Industry TRx: -0.2% w/w; +8.3% y/y
Vascepa
TRx 59,420; -4.1% (-2,561) w/w; -18.6% y/y
NRx 27,716; -6.3% (-1,863) w/w; -17.6% y/y
Ref 31,704; -2.2% (-698) w/w; -19.4% y/y
Fake Vascepa
TRx 45,676; -1.1% (-492) w/w; As % of total V: 43.5%
NRx 22,423; -2.0% (-456) w/w; As % of total V: 44.7%
Ref 23,252; -2.2% (-36) w/w; As % of total V: 42.3%
Fake Vascepa by Manufacturer
Hikma TRx 16,463; Gen share 36.0% Total V share 15.7%
Reddy TRx 18,831; Gen share 41.2%; Total V share 17.9%
Apotex TRx 8,576; Gen share 18.8%; Total V share 8.2%
Teva TRx 897; Gen share 2.0%; Total V share 0.9%
Northstar TRx 908; Gen share 2.0%; Total V share 0.9%
Vascepa + Fake Vascepa
TRx 105,096; -2.8% (-3,054) w/w; +1.4% y/y
NRx 50,140; -4.4% (-2,319) w/w; -1.1% y/y
Ref 54,956; -1.3% (-734) w/w; +3.9% y/y
Lovaza (Fake & Brand)
TRx 64,652; -3.7% (-2,473) w/w; +2.0% y/y
NRx 32,995; -2.8% (-942) w/w; -0.3% y/y
Ref 31,657; -4.6% (-1,531) w/w; +4.5% y/y
Bhatt.
Icosapent ethyl reduces ischemic events in high-risk patients with recent ACS https://t.co/6rURKZ81xI #cardiology #cardiotwitter #prevention @gabrielsteg @mmillermd1 #ACC23
— Dr. Deepak L. Bhatt (@DLBHATTMD) March 22, 2023
Pretty outrageous that after multiple (4-5) attempts to obtain by approved Formulary Exemption form from BCBS-FEP, I'm still unable to do so. They gave me some nonsensical reason.
I was hoping to share it with others here who are going through the same route.
I had these in reverse.
Drug Industry TRx: +7.8% w/w; -0.5% y/y
is actually:
Drug Industry TRx: -0.5% w/w; +7.8% y/y
Scripts for week ending March 10, 2023
Drug Industry TRx: +7.8% w/w; -0.5% y/y
Vascepa
TRx 61,981; +0.9% (+576) w/w; -12.7% y/y
NRx 29,579; +3.3% (+947) w/w; -11.0% y/y
Ref 32,402; -1.1% (-370) w/w; -14.2% y/y
Fake Vascepa
TRx 46,168; +0.2% (+94) w/w; As % of total V: 42.7%
NRx 22,880; -0.1% (-17) w/w; As % of total V: 43.6%
Ref 23,288; +2.8% (+111) w/w; As % of total V: 41.8%
Fake Vascepa by Manufacturer
Hikma TRx 17,291; Gen share 37.5% Total V share 16.0%
Reddy TRx 18,567; Gen share 40.2%; Total V share 17.2%
Apotex TRx 8,724; Gen share 18.9%; Total V share 8.1%
Teva TRx 746; Gen share 1.6%; Total V share 0.7%
Northstar TRx 840; Gen share 1.8%; Total V share 0.8%
Vascepa + Fake Vascepa
TRx 108,149; +0.6% (+670) w/w; +6.4% y/y
NRx 52,459; +1.8% (+929) w/w; +3.3% y/y
Ref 55,691; -0.5% (-259) w/w; +9.6% y/y
Lovaza (Fake & Brand)
TRx 67,125; +1.6% (+1,069) w/w; +5.7% y/y
NRx 33,937; +2.7% (+900) w/w; +2.1% y/y
Ref 33,188; +0.5% (+169) w/w; +9.7% y/y
Excellent.
No excuse for anyone to get the Generic.
If you want to wait ... I requested BCBS to send me the formulary exception form that they approved ... I should receive it within the next week and can share with you how the doctor filled it out.
Rose, Z, other who've tried - what's the status of your fight with BCBS-FEP?
Both have the same amount of IPE.
Scripts for week ending March 3, 2023
Drug Industry TRx: +4.6% w/w; +6.9% y/y
Vascepa
TRx 61,405; +7.2% (+4,146) w/w; -18.7% y/y
NRx 28,632; +8.0% (+2,124) w/w; -20.3% y/y
Ref 32,773; +6.6% (+2,022) w/w; -17.3% y/y
Fake Vascepa
TRx 46,074; +3.3% (+1,469) w/w; As % of total V: 42.9%
NRx 22,897; +3.8% (+848) w/w; As % of total V: 44.4%
Ref 23,177; +2.8% (+621) w/w; As % of total V: 41.4%
Fake Vascepa by Manufacturer
Hikma TRx 16,937; Gen share 36.8% Total V share 15.8%
Reddy TRx 19,019; Gen share 41.3%; Total V share 17.7%
Apotex TRx 8,713; Gen share 18.9%; Total V share 8.1%
Teva TRx 692; Gen share 1.5%; Total V share 0.6%
Northstar TRx 714; Gen share 1.5%; Total V share 0.7%
Vascepa + Fake Vascepa
TRx 107,479; +5.5% (+5,615) w/w; +1.3% y/y
NRx 51,530; +6.1% (+2,972) w/w; -4.2% y/y
Ref 55,950; +5.0% (+2,644) w/w; +7.2% y/y
Lovaza (Fake & Brand)
TRx 66,056; +5.4% (+3,377) w/w; +0.8% y/y
NRx 33,037; +3.5% (+1,105) w/w; -3.6% y/y
Ref 33,019; +7.4% (+2,272) w/w; +5.6% y/y
Not us. More competition.